Literature DB >> 19343087

Differential effect of low dose thiazides on the Renin Angiotensin system in genetically hypertensive and normotensive rats.

Jewell A Jessup1, K Bridget Brosnihan, Patricia E Gallagher, Mark C Chappell, Carlos M Ferrario.   

Abstract

Fifty years since their introduction, thiazide diuretics are established as first-line therapy in the treatment of hypertension. Because the dosing profile for thiazide agents lessened, the mechanism responsible for the blood pressure lowering effect may lie outside their diuretic properties. We evaluated the mechanism driving blood pressure reductions in spontaneously hypertensive rats (SHR) and normotensive WKY by examining the effects of low-dose hydrochlorothiazide (HCTZ) administration on renin-angiotensin system (RAS) components. The 7-day, 1.5 mg/kg/day HCTZ did not change systolic pressure in WKY, but decreased SBP by 41 +/- 2 mm Hg (p < 0.0001) in SHR. This reduction was independent of increases in water intake, urine output, or alterations in electrolyte excretion. HCTZ significantly increased the plasma concentrations of angiotensin I (Ang I) and angiotensin II (Ang II) in both WKY and SHR while reducing angiotensin converting enzyme (ACE) activity and the Ang II/Ang I ratio (17.1 +/- 2.9 before versus 10.3 +/- 2.9 after, p < 0.05) only in SHR. HCTZ increased cardiac ACE2 mRNA and activity, and neprilysin mRNA in WKY, but not SHR. Conversely in SHR, ACE2 activity was decreased and aside from a 75% increase in AT(1) mRNA in the HCTZ-treated SHR, the expression of the other variables remained unaltered. Measures of cardiac mas receptor mRNA showed no changes in response to treatment in both strains, although cardiac mas mRNA was significantly lower in untreated SHR. These data, which document for the first time the effect of low-dose thiazide on the activity of the ACE2/Ang-(1-7)/mas-receptor axis, suggest that the opposing arm of the system does not substantially contribute to the antihypertensive effect of low-dose thiazides in SHR.

Entities:  

Keywords:  AT1 receptor; angiotensin II; angiotensin converting enzyme 2; angiotensin-(1-7); hydrochlorothiazide; hypertension

Year:  2008        PMID: 19343087      PMCID: PMC2409168          DOI: 10.1016/j.jash.2007.10.005

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  26 in total

Review 1.  Studies in hemodynamics and hypertension.

Authors:  E D Freis
Journal:  Hypertension       Date:  2001-07       Impact factor: 10.190

2.  Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.

Authors:  Mark C Chappell; Patricia E Gallagher; David B Averill; Carlos M Ferrario; K Bridget Brosnihan
Journal:  Hypertension       Date:  2003-07-21       Impact factor: 10.190

3.  Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase.

Authors:  Zhiming Zhu; Shanjun Zhu; Daoyan Liu; Tingbing Cao; Lijuan Wang; Martin Tepel
Journal:  Hypertension       Date:  2004-12-20       Impact factor: 10.190

4.  Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide.

Authors:  P Pickkers; R S Garcha; M Schachter; P Smits; A D Hughes
Journal:  Hypertension       Date:  1999-04       Impact factor: 10.190

Review 5.  Diuretics and blood pressure reduction: physiologic aspects.

Authors:  W H Birkenhäger
Journal:  J Hypertens Suppl       Date:  1990-06

6.  Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.

Authors:  Carlos M Ferrario; Jewell Jessup; Patricia E Gallagher; David B Averill; K Bridget Brosnihan; E Ann Tallant; Ronald D Smith; Mark C Chappell
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

Review 7.  Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.

Authors:  Barry L Carter; Michael E Ernst; Jerome D Cohen
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

8.  Direct vascular actions of hydrochlorothiazide and indapamide in isolated small vessels.

Authors:  J A Calder; M Schachter; P S Sever
Journal:  Eur J Pharmacol       Date:  1992-09-10       Impact factor: 4.432

9.  Angiotensin(1-7) in the spontaneously hypertensive rat.

Authors:  K Kohara; K B Brosnihan; C M Ferrario
Journal:  Peptides       Date:  1993 Sep-Oct       Impact factor: 3.750

10.  Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats.

Authors:  J Joyner; L A A Neves; J P Granger; B T Alexander; D C Merrill; M C Chappell; C M Ferrario; W P Davis; K B Brosnihan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-04-11       Impact factor: 3.619

View more
  10 in total

1.  Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats.

Authors:  Anyi Wang; Takuo Hirose; Yusuke Ohsaki; Chika Takahashi; Emiko Sato; Ikuko Oba-Yabana; Satoshi Kinugasa; Yoshikazu Muroya; Sadayoshi Ito; Takefumi Mori
Journal:  Clin Exp Nephrol       Date:  2018-11-13       Impact factor: 2.801

2.  Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment.

Authors:  Janni M Jensen; Frank H Mose; Anna-Ewa O Kulik; Jesper N Bech; Robert A Fenton; Erling B Pedersen
Journal:  World J Nephrol       Date:  2015-07-06

Review 3.  Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities.

Authors:  Hao Wang; Amit K Saha; Xuming Sun; Neal D Kon; Carlos M Ferrario; Leanne Groban
Journal:  Curr Opin Anaesthesiol       Date:  2021-04-01       Impact factor: 2.706

Review 4.  The Angiotensin-(1-12)/Chymase axis as an alternate component of the tissue renin angiotensin system.

Authors:  Carlos M Ferrario; Leanne Groban; Hao Wang; Che Ping Cheng; Jessica L VonCannon; Kendra N Wright; Xuming Sun; Sarfaraz Ahmad
Journal:  Mol Cell Endocrinol       Date:  2020-12-10       Impact factor: 4.369

5.  Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.

Authors:  Katherine Mackey; Valerie J King; Susan Gurley; Michael Kiefer; Erik Liederbauer; Kathryn Vela; Payten Sonnen; Devan Kansagara
Journal:  Ann Intern Med       Date:  2020-05-15       Impact factor: 25.391

6.  Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies.

Authors:  Hisashi Kai; Mamiko Kai; Hiroshi Niiyama; Norihito Okina; Motoki Sasaki; Takanobu Maeda; Atsushi Katoh
Journal:  Hypertens Res       Date:  2021-03-10       Impact factor: 3.872

Review 7.  Renin-angiotensin-aldosterone system and COVID-19 infection.

Authors:  Joachim Alexandre; Jean-Luc Cracowski; Vincent Richard; Béatrice Bouhanick
Journal:  Ann Endocrinol (Paris)       Date:  2020-04-21       Impact factor: 2.478

8.  Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.

Authors:  Hajira Dambha-Miller; Ali Albasri; Sam Hodgson; Christopher R Wilcox; Shareen Khan; Nazrul Islam; Paul Little; Simon J Griffin
Journal:  BMJ Open       Date:  2020-09-14       Impact factor: 2.692

9.  Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.

Authors:  Ann Z Bauer; Rebecca Gore; Susan R Sama; Richard Rosiello; Lawrence Garber; Devi Sundaresan; Anne McDonald; Patricia Arruda; David Kriebel
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-11-21       Impact factor: 3.738

10.  Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients.

Authors:  Annina S Vischer; Gabriela M Kuster; Raphael Twerenbold; Otmar Pfister; Qian Zhou; Andrea Villiger; Marko Poglitsch; Stephan Krähenbühl; Michael Mayr; Stefan Osswald; Manuel Haschke; Thilo Burkard
Journal:  Cells       Date:  2021-03-03       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.